company background image
SPHR.Y logo

Starpharma Holdings OTCPK:SPHR.Y Stock Report

Last Price

US$0.82

Market Cap

US$33.6m

7D

-3.5%

1Y

-74.3%

Updated

28 Mar, 2024

Data

Company Financials

Starpharma Holdings Limited

OTCPK:SPHR.Y Stock Report

Market Cap: US$33.6m

SPHR.Y Stock Overview

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide.

SPHR.Y fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Starpharma Holdings Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Starpharma Holdings
Historical stock prices
Current Share PriceAU$0.82
52 Week HighAU$3.45
52 Week LowAU$0.77
Beta0.82
1 Month Change-6.79%
3 Month Change-34.08%
1 Year Change-74.29%
3 Year Change-94.66%
5 Year Change-89.46%
Change since IPO-87.01%

Recent News & Updates

Recent updates

Shareholder Returns

SPHR.YUS PharmaceuticalsUS Market
7D-3.5%2.2%0.2%
1Y-74.3%25.5%28.1%

Return vs Industry: SPHR.Y underperformed the US Pharmaceuticals industry which returned 25.8% over the past year.

Return vs Market: SPHR.Y underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is SPHR.Y's price volatile compared to industry and market?
SPHR.Y volatility
SPHR.Y Average Weekly Movement10.0%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: SPHR.Y's share price has been volatile over the past 3 months.

Volatility Over Time: SPHR.Y's weekly volatility has decreased from 18% to 10% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199745Cheryl Maleyhttps://starpharma.com

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers.

Starpharma Holdings Limited Fundamentals Summary

How do Starpharma Holdings's earnings and revenue compare to its market cap?
SPHR.Y fundamental statistics
Market capUS$33.56m
Earnings (TTM)-US$5.47m
Revenue (TTM)US$6.86m

4.9x

P/S Ratio

-6.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SPHR.Y income statement (TTM)
RevenueAU$10.52m
Cost of RevenueAU$11.68m
Gross Profit-AU$1.16m
Other ExpensesAU$7.24m
Earnings-AU$8.39m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.02
Gross Margin-11.02%
Net Profit Margin-79.79%
Debt/Equity Ratio0%

How did SPHR.Y perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.